Beta-blocker with alpha-1 antagonist activity

This page covers all Beta-blocker with alpha-1 antagonist activity drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor.

Targets

Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Marketed (2)

• Comparator: carvedilol · Organon and Co · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• Carvedilol alone · Taipei Veterans General Hospital, Taiwan · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking properties that reduces heart rate, blood pressure, and cardiac workload.

Phase 3 pipeline (2)

• Carvedilol IR 25mg, BID · Chong Kun Dang Pharmaceutical · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
• Carvedilol IR 25mg, QD · Chong Kun Dang Pharmaceutical · Cardiovascular
  Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.

Patent intelligence

• beta blocker with alpha 1 antagonist activity patent landscape — aggregated cliff calendar, attackable patents, originator estates